A Phase I, Open-label, Multicenter Dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Volitinib in Patients With Advanced Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 17 Jul 2019
Price : $35 *
At a glance
- Drugs Savolitinib (Primary)
- Indications Gastric cancer; Lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Hutchison MediPharma
- 11 Jul 2019 Status changed from recruiting to completed.
- 08 May 2018 Planned number of patients changed from 70 to 95.
- 08 May 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2020.